NPR’s Rob Stein was reporting on what he described as “among the most exciting developments in cancer research in years” — a ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Holdings announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark ...

CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and ...

A LIVING cancer drug has been proven to work against solid tumours for the first time. Immune-boosting CAR-T therapy removes ...

Cancer patients given experimental treatment that programmes the body to attack rogue cells live 40 per cent longer, major research shows.

Indore: MGM Medical College on Saturday announced its successful treatment of a blood cancer patient using CAR T-cell therapy ...

Chimeric Antigen Receptor or CAR T-cell therapy, the groundbreaking method of treatment, has given new hope to cancer ...

Anktiva is designed to address BCG-unresponsive bladder cancer through its mechanism as an interleukin-15 superagonist.

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce ...

Local immune effector cell–associated toxicity syndrome is a newly identified side effect observed in many patients receiving CD19-targeting CAR T-cell therapy for autoimmune conditions.